Avalo Therapeutics (AVTX) EBT (2014 - 2026)
Avalo Therapeutics (AVTX) reported EBT of -$19.6 million for Q1 2026, down 49.29% on a YoY basis from -$38.7 million in Q1 2025, and down 44.36% quarter-over-quarter from -$13.6 million in Q4 2025.
Avalo Therapeutics (AVTX) EBT (2014 - 2026) Analysis & Trends
Avalo Therapeutics has reported EBT for 13 years, with the latest figure at -$19.6 million in Q1 2026.
- For the quarter ending Q1 2026, EBT fell 49.29% year-over-year to -$19.6 million; the trailing twelve-month figure through Mar 2026 stood at -$84.6 million (down 215.65% YoY), and the FY2025 full-year result was -$78.1 million, down 123.03% from the prior year.
- EBT for Q1 2026 stood at -$19.6 million, down from -$13.6 million in the prior quarter.
- The five-year high for EBT was $98.5 million in Q2 2024, with the low at -$121.3 million in Q1 2024.
- Historically, EBT has averaged -$12.1 million across 5 years, with a median of -$13.0 million in 2022.
- The largest YoY upside for EBT was 1302.91% in 2024 against a maximum downside of 1119.29% in 2024.
- Avalo Therapeutics' EBT stood at -$9.8 million in 2022, then advanced by 16.6% to -$8.2 million in 2023, then slumped by 330.78% to -$35.2 million in 2024, then surged by 61.42% to -$13.6 million in 2025, then slumped by 44.36% to -$19.6 million in 2026.
- The last three EBT figures came in at -$19.6 million (Q1 2026), -$13.6 million (Q4 2025), and -$30.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 19.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.18 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.31 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Avalo Therapeutics | 295.77 Mn | 295.77 Mn | - | -19.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.62 Mn |
| Dec 31, 2025 | -13.59 Mn |
| Sep 30, 2025 | -30.61 Mn |
| Jun 30, 2025 | -20.75 Mn |
| Mar 31, 2025 | -13.14 Mn |
| Dec 31, 2024 | -35.23 Mn |
| Sep 30, 2024 | 23.02 Mn |
| Jun 30, 2024 | 98.47 Mn |
| Mar 31, 2024 | -121.28 Mn |
| Dec 31, 2023 | -8.18 Mn |
| Sep 30, 2023 | -5.22 Mn |
| Jun 30, 2023 | -8.19 Mn |
| Mar 31, 2023 | -9.95 Mn |
| Dec 31, 2022 | -9.80 Mn |
| Sep 30, 2022 | 3.20 Mn |
| Jun 30, 2022 | -12.98 Mn |
| Mar 31, 2022 | -22.04 Mn |
| Dec 31, 2021 | -19.15 Mn |
| Sep 30, 2021 | -17.46 Mn |
| Jun 30, 2021 | -17.37 Mn |